Company: TYRA
Filing Date: 2025-04-18
Form Type: DEF 14A
Source: 0001193125-25-085709
Chunk: 37

Company: Tyra Biosciences, Inc.
Filing Date: 2025-04-18
Form: DEF 14A
Chunk 37
---
 62,383 |     |           |  7.14 |     |            | 9/5/2032  |
|                      |     |            | 7/28/2023 | -1 |     |             |  38,958 |     |               |  71,042 |     |           | 14.35 |     |            | 7/27/2033 |
|                      |     |            | 8/14/2024 | -1 |     |             |   9,583 |     |               | 105,417 |     |           | 21.57 |     |            | 8/13/2034 |

| (1) | The options vest in substantially equal monthly installments over a period of four years from the applicable vesting commencement date, subject to continued service through each vesting date. The vesting commencement date for the option granted on March 10, 2021 is March 5, 2021. The vesting commencement date for the other options is the grant date. The options may be subject to accelerated vesting in certain circumstances as described below under the subsection titled “Employment Arrangements with our Named Executive Officers.” |

| (2) | The options granted on November 2, 2021 vested and became exercisable upon the filing of an Investigational New Drug Application for TYRA-300 with the Food and Drug Administration on June 24, 2022. |

| (3) | The options vest over a period of four years, with 25% of the shares vesting on the one-year anniversary of the grant date, and the remaining shares underlying the options vesting in equal monthly installments thereafter, subject to Dr. Warner’s continued service. The options may be subject to accelerated vesting in certain circumstances as described below under the subsection titled “Employment Arrangements with our Named Executive Officers.” |

| (4) | The options vest in substantially equal monthly installments over a period of three years from the applicable vesting commencement date, subject to continued service through each vesting date. |

24

#### Employment Arrangements with our Named Executive OfficersDr.Harris.We have entered into an employment agreement with Dr. Harris which governs the terms of his employment with us.Dr. Harris’ employment agreement provides for the following benefits in connection with a change in control (as such term is defined below). In the event of a change in control, the vesting